Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 1,265 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Pre-Screening Clear all

Conditions: Alcoholism
Interventions: Quantity Frequency Model, Targets Subjective Drunkenness; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Type 2 Diabetes, Pregnancy
Interventions: Not listed
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer, Financial Hardship
Interventions: CostCOM (Cost Communication, Financial navigation and counseling), Provision of local and national resources to address financial and social needs, Financial Education, Usual care, Screening for financial and social needs; Behavioral · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Costa Mesa, California • Fountain Valley, California • Irvine, California + 3 more

Conditions: Athletic Injuries
Interventions: Pre-season strength and conditioning program; Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 14 Years to 18 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2029
U.S. locations: 1
States / cities: League City, Texas

Conditions: Familial Hypercholesterolaemia
Interventions: Alert-based computerized decision support; Device
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intracranial Hematoma
Interventions: Infrascanner Model 2000; Device
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Resistance Exercise, Aerobic Exercise, Behavioral Group Counseling; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
Interventions: Color fundus photography, Mydriatic Agent; Procedure · Drug
Lead sponsor: Eyenuk, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 942 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glioblastoma
Interventions: Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115; Drug
Lead sponsor: David Reardon, MD; Other
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions: Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography, Durvalumab, Magnetic Resonance Imaging of the Brain with and without Contrast, Monalizumab, Oleclumab, Radiation Therapy; Radiation · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 56
States / cities: Atlanta, Georgia • Augusta, Georgia • Boise, Idaho + 42 more

Conditions: Social Determinants of Health, Primary Care, Diabetes Mellitus, Type 2, Hypertension, Non-medical Health-related Needs, Contextual Drivers of Health
Interventions: Implementation Support; Other
Lead sponsor: OCHIN, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anus Neoplasms
Interventions: Self-anal exam arm; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 27 Years to 80 Years · Male only
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: HCV Screening; Other
Lead sponsor: Denver Health and Hospital Authority; Other
Eligibility: 18 Years and older
Enrollment: 147,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Denver, Colorado • Baltimore, Maryland • Jackson, Mississippi

Conditions: Healthy Adult Participants
Interventions: Diagnostic procedures, Drug Screening; Diagnostic Test · Device
Lead sponsor: Intelligent Bio Solutions Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: E-Cig Use
Interventions: Hyperpolarized Xenon -129 MRI; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Obesity, Surgery
Interventions: Stable isotope infusion; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Endometrial Cancer
Interventions: Tirzepatide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Genetic Disease, Pediatrics, Predictive Model, Clinical Decision Support
Interventions: SIGHT Prompted Provider Message; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 1 Year to 20 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Astrocytoma, Resectable Glioblastoma
Interventions: Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pembrolizumab, Surgical Procedure; Procedure · Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections, Lipodystrophy, Insulin Resistance
Interventions: Avandia administration for 6-12 weeks; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Smoking, Cigarette, Smoking Cessation
Interventions: Varenicline, Combination nicotine patch and nicotine mini-lozenge treatment, Monetary incentives for initiating treatment, Automated tailored outreach, Care management, Wisconsin Tobacco Quit Line referral, Primary care provider referral, Untailored outreach, Multiple smoking cessation coaching calls; Drug · Behavioral · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Human Papilloma Virus (HPV), Cervical Cancers
Interventions: Self-sampling with urine, Self-sampling with swab, In-clinic Pap/HPV co-testing; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 735 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Breast Cancer, Peripheral Neuropathy
Interventions: Acupuncture, Neuropathic Pain Scale (NPS) questionnaire, FACT/GOG-Ntx questionnaire; Procedure · Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Harrison, New York • New York, New York

Conditions: High Cardiovascular Risk, Hypertension
Interventions: Zilebesiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 139
States / cities: Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more

Search by objective public record fields.

The Teachable Moment: Screening and Brief Intervention for Admitted Trauma Patients

Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes

Addressing Financial and Social Needs Among Patients With Cancer

Identification of Neuromusculoskeletal Variables Associated With Injury Risk and Performance in High School Athletes.

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection in Children

Exercising Our ABC's (African- American Breast Cancer Survivors)

Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

DEDICATE: aDvancing carE Management aDoption In Community heAlTh cEnters

The Feasibility of Self or Partner-assisted Digital Anal Exam Screening

The DETECT HCV Screening Trial

Usability Evaluation of the Intelligent Fingerprinting Drug Screening System

Hyperpolarized Xenon-129 MR Imaging of the Lung

Omics Profiling of Weight Loss With Bariatric Surgery

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Clinical Decision Support to Identify Pediatric Patients With Undiagnosed Genetic Disease

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome

Health Systems Reach Interventions Project

Unidos Contra el VPH

Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)